BRPI0514865A - processo para preparar um composto - Google Patents

processo para preparar um composto

Info

Publication number
BRPI0514865A
BRPI0514865A BRPI0514865-0A BRPI0514865A BRPI0514865A BR PI0514865 A BRPI0514865 A BR PI0514865A BR PI0514865 A BRPI0514865 A BR PI0514865A BR PI0514865 A BRPI0514865 A BR PI0514865A
Authority
BR
Brazil
Prior art keywords
oxo
preparing
compound
indolines
dioxo
Prior art date
Application number
BRPI0514865-0A
Other languages
English (en)
Inventor
George W Muller
Roger Chen
Manohar Tukaram Saindane
Chuansheng Ge
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514865(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BRPI0514865A publication Critical patent/BRPI0514865A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PROCESSO PARA PREPARAR UM COMPOSTO A presente invenção refere-se aos processos novos para a preparação de 2-(2,6-dioxo-piperidin-3-il)-1-oxo-indolinas substituídas que são úteis para a prevenção ou o tratamento de doenças ou condições relacionadas com uma atividade ou nível anormalmente alto de TNF<244>. A invenção proporciona processos para a produção comercial de 2-(2,6-dioxo-piperidin-3-il)-1-oxo-indolinas substituídas incluindo, mas não limitado a, 3-(4-amino-1-oxo-isoindolin-2-il)-piperidina-2,6-diona terapeuticamente ativa.
BRPI0514865-0A 2004-09-03 2005-08-31 processo para preparar um composto BRPI0514865A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60740904P 2004-09-03 2004-09-03
PCT/US2005/031318 WO2006028964A1 (en) 2004-09-03 2005-08-31 Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines

Publications (1)

Publication Number Publication Date
BRPI0514865A true BRPI0514865A (pt) 2008-06-24

Family

ID=35385616

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514865-0A BRPI0514865A (pt) 2004-09-03 2005-08-31 processo para preparar um composto

Country Status (22)

Country Link
US (1) US7863451B2 (pt)
EP (2) EP2479172B1 (pt)
JP (2) JP2008512379A (pt)
KR (1) KR20070057907A (pt)
CN (1) CN101080400A (pt)
AR (1) AR050724A1 (pt)
AU (1) AU2005282728A1 (pt)
BR (1) BRPI0514865A (pt)
CA (1) CA2579291C (pt)
ES (2) ES2437592T3 (pt)
GT (1) GT200500242A (pt)
HN (1) HN2005000508A (pt)
IL (1) IL181674A0 (pt)
MX (1) MX2007002521A (pt)
NZ (1) NZ554068A (pt)
PA (1) PA8643901A1 (pt)
PE (1) PE20060648A1 (pt)
SV (1) SV2007002219A (pt)
TW (1) TW200621748A (pt)
UY (1) UY29097A1 (pt)
WO (1) WO2006028964A1 (pt)
ZA (1) ZA200702382B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
KR101299321B1 (ko) 2005-06-30 2013-08-26 셀진 코포레이션 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법
CN101186611B (zh) * 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
MX2010009344A (es) * 2008-03-11 2012-09-28 Reddys Lab Ltd Dr Preparacion de lenalidomida.
DE102008057335A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Amorphes Lenalidomid
DE102008057285A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
DE102008057284A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
EP2350055A4 (en) * 2008-11-17 2012-04-18 Reddys Lab Ltd Dr LENALIDOMIDE OLVATE AND PROCESS
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
PL2403845T3 (pl) * 2009-03-02 2014-09-30 Generics Uk Ltd Ulepszony sposób
CN101580501B (zh) 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
AU2009350978A1 (en) * 2009-08-12 2012-04-05 Synthon B.V. Lenalidomide salts
WO2011033468A1 (en) * 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Process for the preparation of a crystalline form of lenalidomid
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011050962A1 (en) 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN102127054B (zh) * 2009-11-02 2013-04-03 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102060842B (zh) * 2009-11-02 2013-05-08 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011069608A1 (en) * 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
HUE042011T2 (hu) 2010-02-11 2019-06-28 Celgene Corp Arilmetoxi-izoindolin-származékok, azok készítményei és alkalmazási módszereik
CN102453021A (zh) * 2010-10-22 2012-05-16 重庆医药工业研究院有限责任公司 来那度胺的新晶型及其制备方法
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
CA2842316A1 (en) 2011-07-19 2013-01-24 Amplio Pharma, Llc Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)­piperidine-2,6-dione
WO2014018866A1 (en) * 2012-07-27 2014-01-30 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
KR20150041650A (ko) 2012-08-09 2015-04-16 셀진 코포레이션 (ｓ)-3-(4-((4-(모르폴리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 및 이의 약학적으로 허용가능한 형태의 제조를 위한 공정
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CN103242215A (zh) * 2013-05-27 2013-08-14 合肥医工医药有限公司 一种来那度胺中间体的制备方法
WO2016024286A2 (en) 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
CN105566290B (zh) * 2014-10-30 2020-05-22 康朴生物医药技术（上海）有限公司 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
CN104447689B (zh) * 2014-12-22 2016-07-20 上海迈柏医药科技有限公司 来那度胺的晶型及其制备方法
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN108191826A (zh) * 2018-01-08 2018-06-22 浙江省医学科学院 一种来那度胺晶体及其制备方法
AU2019261273B2 (en) 2018-04-23 2023-03-09 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
ES2963694T3 (es) 2018-07-10 2024-04-01 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2)
WO2020048546A1 (zh) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 三环取代哌啶二酮类化合物
EP3880669A1 (en) 2018-11-13 2021-09-22 Biotheryx, Inc. Substituted isoindolinones
CN109369504B (zh) * 2018-12-06 2020-05-12 温州大学 含硫3-亚甲基异吲哚啉-1-酮衍生物的制备方法
WO2025118133A1 (zh) * 2023-12-05 2025-06-12 浙江普洛家园药业有限公司 一种(s)-来那度胺-5-位衍生物及其合成方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE4236880A1 (de) * 1992-10-31 1994-05-05 Basf Ag N-Phenyl substituierte Glutarimide und N-Phenylglutarsäureamide, deren Herstellung und Verwendung
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
KR100534498B1 (ko) * 1996-07-24 2005-12-08 셀진 코포레이션 치환된 2-(2,6-디옥소피페리딘-3-일)-프탈이미드와 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린과 ＴＮＦα농도를 감소시키는 방법
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE69739181D1 (de) 1996-08-12 2009-02-05 Celgene Corp Neue immunotherapeutische Mittel und deren Verwendung in der Reduzierung von Cytokinenspiegel
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
ES2243052T3 (es) 1998-03-16 2005-11-16 Celgene Corporation Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
EP1163219B1 (en) * 1999-03-18 2005-10-12 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
EP1193248A1 (en) * 2000-09-30 2002-04-03 Aventis Pharma Deutschland GmbH Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
NZ526683A (en) 2000-11-30 2008-03-28 Childrens Medical Center Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
JP2002284761A (ja) * 2001-01-17 2002-10-03 Toray Ind Inc 光学活性３−アミノピロリジン−２，５−ジオン誘導体および光学活性３−アミノピロリジン誘導体の製造方法
DK1423115T3 (da) * 2001-08-06 2009-06-15 Childrens Medical Center Nitrogen-substituerede thalidomidanalogers antiangiogenetiske aktivitet
US7091343B2 (en) 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CH696542A5 (de) * 2003-07-09 2007-07-31 Siegfried Ltd Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
KR101299321B1 (ko) 2005-06-30 2013-08-26 셀진 코포레이션 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법
JP5578785B2 (ja) 2005-08-31 2014-08-27 セルジーン コーポレイション イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
DK2076260T3 (da) 2006-09-15 2011-06-27 Celgene Corp N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
MX2010009344A (es) 2008-03-11 2012-09-28 Reddys Lab Ltd Dr Preparacion de lenalidomida.
CN101531653B (zh) 2008-03-13 2014-07-09 峡江和美药业有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用

Also Published As

Publication number Publication date
ZA200702382B (en) 2008-08-27
HN2005000508A (es) 2010-10-08
US7863451B2 (en) 2011-01-04
UY29097A1 (es) 2006-03-31
TW200621748A (en) 2006-07-01
EP2479172A1 (en) 2012-07-25
ES2438725T3 (es) 2014-01-20
JP2012207040A (ja) 2012-10-25
IL181674A0 (en) 2007-07-04
SV2007002219A (es) 2007-03-20
WO2006028964A1 (en) 2006-03-16
AR050724A1 (es) 2006-11-15
EP2479172B1 (en) 2013-10-09
ES2437592T3 (es) 2014-01-13
GT200500242A (es) 2006-06-22
EP1797068B1 (en) 2013-10-09
JP2008512379A (ja) 2008-04-24
JP5701824B2 (ja) 2015-04-15
PA8643901A1 (es) 2006-05-16
CA2579291A1 (en) 2006-03-16
MX2007002521A (es) 2007-05-09
KR20070057907A (ko) 2007-06-07
CA2579291C (en) 2011-11-29
PE20060648A1 (es) 2006-07-14
US20060052609A1 (en) 2006-03-09
AU2005282728A1 (en) 2006-03-16
CN101080400A (zh) 2007-11-28
NZ554068A (en) 2009-07-31
EP1797068A1 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
BRPI0514865A (pt) processo para preparar um composto
MX2022007105A (es) Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
ATE382353T1 (de) Substiuierte piperidine als melanocortinrezeptor- modulatoren
NO20070893L (no) Hydantoinderivater for behandling av inflammasjonslidelser.
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
TW200612911A (en) Compounds for the treatment of inflammatory disorders
NO20063928L (no) Substituerte kinolinforbindelser
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
BRPI0410117A (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
MY141867A (en) Substituted pyrimidines useful as protein kinase inhibitors
NO20083567L (no) Hydantoinderivater for behandling av inflammatoriske forstyrrelser
NO20070917L (no) Imidazotriaziner som protein-kinaseinhibitorer
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20083845L (no) 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
PE20050078A1 (es) Derivados de pirrolidona como inhibidores de maob
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
TW200720260A (en) Prokineticin 1 receptor antagonists
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: REFERENTE A RPI NO 2051 DE 27/04/2010.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2342 DE 24-11-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.